Matthew Johnson is a Psychiatry physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
520 Osborne Rd NE Ste 210
Fridley, MN 554322718
Telephone
763-236-3800Provider last certified this registry record 23 Nov 2025.
Clinical trials
- Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder
Sponsor: Johns Hopkins University
- 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Sponsor: Johns Hopkins University
- Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97.6%SSRI28.5%Sertraline Hcl29%Trazodone Hcl29%Fluoxetine Hcl23%Escitalopram Oxalate10%Paroxetine Hcl10%Part D<11 patientsAtypical Antipsychotic17.5%Quetiapine Fumarate49%Aripiprazole22%Risperidone18%Olanzapine11%Part D<11 patients+ 9 more classes in this area
Cardiovascular
2.4%Central alpha-2 Adrenergic Agonist2.4%Clonidine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
9 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Spatiotemporal Optimization of Deep Brain Stimulation for Parkinson's Disease
University of Minnesota
FY2026$522,942R01NS094206 - Educational Program on Translating Neural Medical Devices
University of Minnesota
FY2026$265,920R25NS132346
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”